RNXT vs APP

AppLovin Corporation (APP) offers the better valuation at 51.

2x trailing P/E (29. 4x forward), making it the more compelling value choice. Analysts rate AppLovin Corporation (APP) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AppLovin Corporation (APP) delivered a total return of +771.

2%, compared to -87. 9% for RenovoRx, Inc. (RNXT). Over 10 years, the gap is even starker: APP returned +618. 6% versus RNXT's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), RenovoRx, Inc.

(RNXT) is the lower-risk stock at 1. 17β versus AppLovin Corporation's 2. 24β — meaning APP is approximately 92% more volatile than RNXT relative to the S&P 500. On balance sheet safety, RenovoRx, Inc. (RNXT) carries a lower debt/equity ratio of 6% versus 166% for AppLovin Corporation — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AppLovin Corporation grew EPS 115.

2% year-over-year, compared to 26. 0% for RenovoRx, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AppLovin Corporation (APP) is the more profitable company, earning 60.

8% net margin versus -205. 0% for RenovoRx, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: APP leads at 75. 8% versus -255. 1% for RNXT. At the gross margin level — before operating expenses — RNXT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, RenovoRx, Inc.

(RNXT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17)). AppLovin Corporation (APP) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RNXT: -88. 1%, APP: +618. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RNXT (Healthcare) and APP (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RNXT is a small-cap quality compounder stock; APP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.